GCT
BMRN icon

Galaxy Capital Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Galaxy Capital Trading’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,000
Closed -$217K – 166
2013
Q3 		$217K Buy
+3,000
New +$199K 0.17% 189

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Galaxy Capital Trading's BMRN Position: Q4 2013 in Review

Galaxy Capital Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2013, closing a stake of 3,000 shares — an estimated $217K sold.

Galaxy Capital Trading first reported a position in BMRN in Q3 2013 and held it in 1 quarter. The position peaked at $217K in Q3 2013. 306 funds tracked by Wall St. Rank hold BMRN as of Q4 2013.

  • Galaxy Capital Trading reported no remaining BioMarin Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Galaxy Capital Trading sold 3,000 BioMarin Pharmaceuticals shares in Q4 2013, an estimated $217K.
  • Galaxy Capital Trading first reported a position in BioMarin Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Galaxy Capital Trading's BioMarin Pharmaceuticals position peaked at $217K in Q3 2013.
  • 306 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2013.

Based on Galaxy Capital Trading's 13F filing for Q4 2013, filed 26 Feb 2014.